Stockwatch: Antibodies And Coronavirus – It’s Complicated
Monoclonal Antibodies Have A Poor Antiviral Track Record
The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.
You may also be interested in...
Also: remdesivir filed in the EU.
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.